Cargando…

Post-tuberculous lung disease: should we be using Theophylline?

Tuberculosis affects 10 million people and over 320,000 South Africans every year. A significant proportion of patients treated for tuberculosis develop post-tuberculous lung disease (PTBLD), a disease of chronic respiratory impairment for which there is a lack of affordable treatment options. PTBLD...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamchand, Sumanth, Williams, Morne, Naidoo, Poobalan, Decloedt, Eric, Allwood, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947523/
https://www.ncbi.nlm.nih.gov/pubmed/33717595
http://dx.doi.org/10.21037/jtd-20-1298
_version_ 1783663247516237824
author Karamchand, Sumanth
Williams, Morne
Naidoo, Poobalan
Decloedt, Eric
Allwood, Brian
author_facet Karamchand, Sumanth
Williams, Morne
Naidoo, Poobalan
Decloedt, Eric
Allwood, Brian
author_sort Karamchand, Sumanth
collection PubMed
description Tuberculosis affects 10 million people and over 320,000 South Africans every year. A significant proportion of patients treated for tuberculosis develop post-tuberculous lung disease (PTBLD), a disease of chronic respiratory impairment for which there is a lack of affordable treatment options. PTBLD a heterogenous disorder that shares phenotypical features with chronic obstructive lung disease, bronchiectasis, lung fibrosis and destruction as well as pulmonary hypertension. There remains a paucity of proven pharmacotherapy for the management of PTBLD. Theophylline, a widely available and affordable medicine that has largely fell out of favour in high-income settings due to its toxicity and narrow therapeutic index, may be repositioned for the treatment of PTBLD. In this review, we unpack the potential role of theophylline in the management of PTBLD by reviewing the evidence for its bronchodilatory, anti-inflammatory and potential pleotrophic effects.
format Online
Article
Text
id pubmed-7947523
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-79475232021-03-12 Post-tuberculous lung disease: should we be using Theophylline? Karamchand, Sumanth Williams, Morne Naidoo, Poobalan Decloedt, Eric Allwood, Brian J Thorac Dis Review Article Tuberculosis affects 10 million people and over 320,000 South Africans every year. A significant proportion of patients treated for tuberculosis develop post-tuberculous lung disease (PTBLD), a disease of chronic respiratory impairment for which there is a lack of affordable treatment options. PTBLD a heterogenous disorder that shares phenotypical features with chronic obstructive lung disease, bronchiectasis, lung fibrosis and destruction as well as pulmonary hypertension. There remains a paucity of proven pharmacotherapy for the management of PTBLD. Theophylline, a widely available and affordable medicine that has largely fell out of favour in high-income settings due to its toxicity and narrow therapeutic index, may be repositioned for the treatment of PTBLD. In this review, we unpack the potential role of theophylline in the management of PTBLD by reviewing the evidence for its bronchodilatory, anti-inflammatory and potential pleotrophic effects. AME Publishing Company 2021-02 /pmc/articles/PMC7947523/ /pubmed/33717595 http://dx.doi.org/10.21037/jtd-20-1298 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Karamchand, Sumanth
Williams, Morne
Naidoo, Poobalan
Decloedt, Eric
Allwood, Brian
Post-tuberculous lung disease: should we be using Theophylline?
title Post-tuberculous lung disease: should we be using Theophylline?
title_full Post-tuberculous lung disease: should we be using Theophylline?
title_fullStr Post-tuberculous lung disease: should we be using Theophylline?
title_full_unstemmed Post-tuberculous lung disease: should we be using Theophylline?
title_short Post-tuberculous lung disease: should we be using Theophylline?
title_sort post-tuberculous lung disease: should we be using theophylline?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947523/
https://www.ncbi.nlm.nih.gov/pubmed/33717595
http://dx.doi.org/10.21037/jtd-20-1298
work_keys_str_mv AT karamchandsumanth posttuberculouslungdiseaseshouldwebeusingtheophylline
AT williamsmorne posttuberculouslungdiseaseshouldwebeusingtheophylline
AT naidoopoobalan posttuberculouslungdiseaseshouldwebeusingtheophylline
AT decloedteric posttuberculouslungdiseaseshouldwebeusingtheophylline
AT allwoodbrian posttuberculouslungdiseaseshouldwebeusingtheophylline